Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Home
/
update
/
details

Indica Labs Unveils AI-Powered Macrodissection Suite to Enhance Molecular Pathology Workflows

NextEdge Admin

02 Aug 2024

2 min 59 sec

Indica Labs has introduced Lung Macrodissect AI, a transformative tool in digital pathology that enhances slide macrodissection and molecular pathology workflows. This AI-powered solution significantly improves the accuracy and efficiency of tumor content estimation and macrodissection, critical steps in molecular pathology. Traditional manual methods are often subjective, error-prone, and labor-intensive. In contrast, Lung Macrodissect AI quantifies tumor content across whole slide images, generating real-time data on tumor cell density to guide the annotation process.

Lung Macrodissect AI integrates with Indica Labs' HALO AP® platform and can pair with Xyall's Tissector robotic macrodissectors for a fully automated workflow. This integration enhances the accuracy and efficiency of the macrodissection process, allowing pathologists to focus on complex tasks. The tool also standardizes manual macrodissection workflows, ensuring only high-quality specimens are sent for genetic sequencing and molecular testing.

Clinical validation of Lung Macrodissect AI on 317 primary and metastatic slides showed significant improvements in consistency and agreement among pathologists. Without AI assistance, the inter-pathologist consistency (ICC) was 0.45 and agreement (Fleiss’ kappa) was 0.27. With AI assistance, the ICC increased to 0.75, and Fleiss’ kappa rose to 0.66, demonstrating substantial improvements.

Steven Hashagen, CEO of Indica Labs, highlighted the efficiency and accessibility advancements brought by Lung Macrodissect AI. Future launches include tools for colon, breast, and prostate macrodissection. Peter Caie, Senior Principal Scientist at Indica Labs, emphasized the tool's ability to objectively quantify tumor cells and streamline the annotation process.

Lung Macrodissect AI is available via the HALO AP® platform, known for its robust annotation, collaboration, and image analysis tools. HALO AP® supports various file types and complies with FDA, HIPAA, and GDPR regulations. While Lung Macrodissect AI is for research use only in the USA, HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland.